Meta-Analysis
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2018; 24(28): 3181-3191
Published online Jul 28, 2018. doi: 10.3748/wjg.v24.i28.3181
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis
Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li
Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China
Author contributions: Jiang XW, Ye JZ, Li YT and Li LJ contributed the data extraction and statistical analysis; Jiang XW wrote the manuscript; Ye JZ, Li YT and Li LJ reviewed the manuscript; all authors have approved the final version of the manuscript.
Supported by the National Natural Science Foundation of China, No. 81330011; and the Science Fund for Creative Research Groups of the National Natural Science Foundation of China, No. 81721091.
Conflict-of-interest statement: There is no conflict of interest in this study.
PRISMA 2009 Checklist statement: The PRISMA checklist has been adopted.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Lan-Juan Li, MD, PhD, Professor, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ljli@zju.edu.cn
Telephone: +86-571-87236759 Fax: +86-571-87236459
Received: March 28, 2018
Peer-review started: March 28, 2018
First decision: May 9, 2018
Revised: June 2, 2018
Accepted: June 22, 2018
Article in press: June 22, 2018
Published online: July 28, 2018
Processing time: 121 Days and 23.8 Hours
ARTICLE HIGHLIGHTS
Research background

Hepatitis B virus/hepatitis C virus (HBV/HCV) dual infection is common in regions with high HBV prevalence, as HBV and HCV share a similar mode of transmission. HBV/HCV-coinfected patients tend to have more severe liver fibrosis and a higher risk of hepatocellular carcinoma than those without coinfection. HBV reactivation may occur after patients receive direct-acting antiviral agent (DAA)-based therapy or interferon (IFN)-based therapy for hepatitis C. Several studies have reported HBV reactivation but a meta-analysis to determine the proportion of HBV reactivation is still lacking.

Research motivation

Although previous studies reported HBV reactivation in patients undergoing DAA-based therapy or IFN-based therapy, the results indicate contradictory HBV reactivation rates. Moreover, the need for preemptive anti-HBV therapy remains controversial.

Research objectives

The main objectives of the systematic review and meta-analysis were to evaluate the incidence of HBV reactivation in patients receiving DAA-based therapy or IFN-based therapy for hepatitis C and the effectiveness of preemptive anti-HBV therapy for preventing HBV reactivation.

Research methods

Relevant publications were searched in the PubMed, MEDLINE and EMBASE databases with the indicated key words and subject terms. The data were extracted, and statistical analysis was conducted in Stata to assess the incidence of HBV reactivation and reactivation-related hepatitis. Significant heterogeneity was investigated using meta-regression and subgroup analyses for treatment regimen, HBV DNA level, study sample size, and race. Publication bias was tested using Egger’s test and was assessed by funnel plots.

Research results

The systematic review identified 7092 articles and enrolled 39 full articles that met the inclusion criteria. The pooled random effects overall HBV reactivation rate was 15.7% (95%CI: 10.6-21.5) in hepatitis B surface antigen (HBsAg)-positive patients. The HBV reactivation rate was higher in the DAA-treated group (21.1%, 95%CI: 15.8-26.9) than in the IFN-treated group (11.9%, 95%CI: 6.3-18.6). The incidence of hepatitis related to HBV reactivation was 0.7% (95%CI: 0-2.6) in HBsAg-positive patients and patients receiving DAA therapy (3.8%, 95%CI: 0.3-9.5) had a higher rate of HBV reactivation-related hepatitis than those receiving IFN-based therapy (0, 95%CI: 0-0.9). Preemptive anti-HBV therapy with entecavir or tenofovir significantly reduced the risk of HBV reactivation in patients receiving DAA-based treatment (RR = 0.31, 95%CI: 0.1-0.96).

Research conclusions

Our study found that HBV reactivation and hepatitis flare occurred more frequently in HBsAg-positive patients receiving DAA-based anti-HCV treatment than in patients receiving IFN-based therapy. HBV reactivation was rare in patients with previous HBV infection. Preemptive anti-HBV therapy with NUCs was effective in HBsAg-positive patients to prevent HBV reactivation, especially in those with detectable serum HBV DNA.

Research perspectives

Our study found the high risk of HBV reactivation in patients receiving DAA-based therapy for hepatitis C. Preemptive anti-HBV treatment proved to be effective in preventing HBV reactivation during DAA therapy. However, more high quality randomized controlled trials are needed to assess the risk of HBV reactivation in patients with HBV/HCV coinfection. Further investigation is required to assess the cost effectiveness of treating HBV/HCV-coinfected patients with NUCs prior to initiating DAA therapy.